Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511

Neumora Therapeutics, Inc.

2025-Q3 EPS reported -$1.10

Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.
Cash, equivalents, and marketable securities $171.5M; expects to fund operations into 2027.
Drew $40M non-dilutive capital from K2 HealthVentures facility.
NMRA-215 (NLRP3 inhibitor) showed class-leading weight loss in DIO mouse models; Phase 1 expected Q1 2026.
NMRA-511 Phase 1b data in Alzheimer's agitation expected around year-end; navacaprant KOASTAL topline in 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.